NeoGenomics gained FDA approval for an IHC companion diagnostic test in North Carolina, which identifies patients eligible for targeted therapy.

1 report, 1 independent Updated Jul 9

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

FDA NeoGenomics North Carolina

Keep exploring

Part of

A company based in Charlotte, North Carolina, has products that comply with FDA guidelines. All 2 developments

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
NeoGenomics
cancer genetics diagnostic testing company based in Fort Myers, Florida, USA
- Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.Sun 02:44
North Carolina
state of the United States of America
- Bills affecting state law are being introduced and debated by the legislative body in North Carolina.Mon 16:59
- Matthew Rutter attended a convention held in North Carolina on June 19, 2026.Mon 15:56

Related events

Nevada is seeking medical treatments outside of FDA approval, a process being tracked by Ballotpedia.Aug 26

Coverage

Newest first; wire copies grouped

Jul 9yahoo.com